Considering that NF-κB could be regarded as the master switch in the regulation of inflammation in macrophages, this study supports the potential use of O-demethylisoquinolinequinones as a therapeutic agents in the treatment of IBD. This evidence concerns the gene NFKB1 and inflammatory bowel disease.